Valuation: NetraMark Holdings Inc.

Market Cap 57.5M 40.53M 35.54M 32.76M 30.67M 3.82B 58.7M 394M 152M 1.89B 152M 149M 6.55B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 57.5M 40.53M 35.54M 32.76M 30.67M 3.82B 58.7M 394M 152M 1.89B 152M 149M 6.55B EV / Sales 2026 *
143x
EV / Sales 2027 * -
Free-Float
87.53%
Yield 2026 *
-
Yield 2027 * -
1 day-6.06%
1 week-21.52%
Current month-30.34%
1 month-31.11%
3 months-31.11%
6 months-45.61%
Current year-43.64%
1 week 0.62
Extreme 0.62
0.79
1 month 0.62
Extreme 0.62
0.9
Current year 0.62
Extreme 0.62
1.28
1 year 0.62
Extreme 0.62
1.8
3 years 0.16
Extreme 0.155
1.8
5 years 0.15
Extreme 0.15
2.75
10 years 0.15
Extreme 0.15
3.17
Manager TitleAgeSince
Chief Executive Officer - 2022-02-16
President - 2022-07-03
Director of Finance/CFO 57 2022-07-17
Director TitleAgeSince
Chairman 40 2025-06-08
Director/Board Member - -
Director/Board Member - 2022-06-15
Date Insider Type Main position Quantity % Market Cap.
04-13Sell

Chief Technology Officer

14,286 0.0154%
04-12Tax

Chairperson

434,178 0.4686%
04-08Tax

Chairperson

434,208 0.4687%
Change 5-day change 1-year change 3-year change Capi.($)
-6.06%-21.52%-54.07%+129.63% 43.13M
+5.71%-1.69%-25.02%+13.50% 2,621B
+5.28%-12.10%-21.71%+710.11% 257B
-3.12%-3.28%+255.84%+972.80% 139B
+2.45%-2.61%+24.23%+69.17% 102B
-0.15%-0.26%-8.34%+8.90% 87.13B
+8.52%+7.52%+82.86%+156.88% 78.65B
+2.61%+0.05%-42.38%+60.26% 54.52B
-0.08%-0.31%-0.33%+66.21% 44.32B
+2.52%-7.70%-54.70%+21.30% 33.21B
Average +0.73%-5.07%+15.64%+220.88% 341.67B
Weighted average by Cap. +0.08%-2.81%-9.21%+111.34%

Financials

2026 *2027 *
Net sales 401K 283K 248K 228K 214K 26.66M 409K 2.74M 1.06M 13.17M 1.06M 1.04M 45.68M -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-
Date Price Change Volume
26-06-26 $0.6200 -6.06% 67,500
26-06-25 $0.6600 -5.71% 73,000
26-06-24 $0.7000 -7.89% 77,120
26-06-23 $0.7600 -3.80% 23,202
26-06-22 $0.7900 0.00% 4,500

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AIAI Stock